Literature DB >> 10696939

Prevalence of Helicobacter pylori infection in 160 patients with Barrett's oesophagus or Barrett's adenocarcinoma.

R V Lord1, D J Frommer, S Inder, D Tran, R L Ward.   

Abstract

BACKGROUND: The role of Helicobacter pylori infection in the development of Barrett's oesophagus and its complications is uncertain. The aim of the present study was to determine the importance of H. pylori infection in this disease by comparing the frequency of oesophageal and gastric H. pylori infection in a group of patients with Barrett's oesophagus or adenocarcinoma, with the frequency of infection in a control group without Barrett's disease.
METHODS: The study group included 160 patients (123 male, 37 female; mean age: 61.2 years) who were classified (according to the highest grade pathological lesion in the oesophagus) as having Barrett's intestinal metaplasia (IM; 88 patients), Barrett's oesophagus with low-grade dysplasia (LGD; 28 patients), high-grade dysplasia (HGD; five patients), Barrett's indefinite for dysplasia (n = 4), and Barrett's adenocarcinoma (33 patients). A total of 91 of these patients had gastric antral specimens available for study. The control group consisted of 214 consecutive, prospectively enrolled symptomatic patients (122 male, 92 female; mean age: 57.2 years) who underwent upper gastrointestinal endoscopy and in whom Barrett's oesophagus or Barrett's adenocarcinoma was not found. A modified Warthin-Starry method was used to detect H. pylori infection.
RESULTS: Oesophageal H. pylori infection was found in eight of 160 (5%) patients with Barrett's oesophagus or Barrett's adenocarcinoma. Holicobacter pylori organisms in the oesophagus were found only on non-intestinalized cardiac or oxyntocardiac mucosa. All patients with oesophageal H. pylori infection and an antral biopsy available for study had antral H. pylori infection. Gastric antral H. pylori infection was significantly less prevalent in patients in the Barrett's study group (15/91, 16.5%) than in the non-Barrett's control group (67/214, 31.3%; Fisher's exact test, P = 0.01). Patients from the control group with an endoscopic diagnosis of duodenal ulcer, gastric ulcer, gastritis, or duodenitis had a significantly higher prevalence of infection compared with the Barrett's group, but there was no difference in the infection prevalence in patients in the Barrett's group and patients with reflux oesophagitis, hiatal hernia, no endoscopic abnormality, or any other diagnosis.
CONCLUSIONS: Oesophageal H. pylori infection is uncommon in patients with Barrett's IM, dysplasia, or adenocarcinoma, and may be restricted to non-intestinalized columnar epithelium. Gastric H. pylori infection may have a protective effect for the development of Barrett's oesophagus.

Entities:  

Mesh:

Year:  2000        PMID: 10696939     DOI: 10.1046/j.1440-1622.2000.01737.x

Source DB:  PubMed          Journal:  Aust N Z J Surg        ISSN: 0004-8682


  15 in total

1.  Helicobacter pylori and esophageal cancer risk: a meta-analysis.

Authors:  Farhad Islami; Farin Kamangar
Journal:  Cancer Prev Res (Phila)       Date:  2008-10

2.  Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia.

Authors:  A P Ireland; D K Shibata; P Chandrasoma; R V Lord; J H Peters; T R DeMeester
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

3.  Human defensin 5 expression in intestinal metaplasia of the upper gastrointestinal tract.

Authors:  B Shen; E M Porter; E Reynoso; C Shen; D Ghosh; J T Connor; J Drazba; H K Rho; T L Gramlich; R Li; A H Ormsby; M-S Sy; T Ganz; C L Bevins
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

4.  The association between Barrett's esophagus and Helicobacter pylori infection: a meta-analysis.

Authors:  Lori A Fischbach; Helena Nordenstedt; Jennifer R Kramer; Subi Gandhi; Sam Dick-Onuoha; Anthony Lewis; Hashem B El-Serag
Journal:  Helicobacter       Date:  2012-03-20       Impact factor: 5.753

5.  Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA.

Authors:  H B El-Serag; A C Mason; N Petersen; C R Key
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

6.  Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study.

Authors:  D A Corley; A Kubo; T R Levin; G Block; L Habel; W Zhao; P Leighton; G Rumore; C Quesenberry; P Buffler; J Parsonnet
Journal:  Gut       Date:  2007-09-25       Impact factor: 23.059

Review 7.  Management of Barrett's esophageal carcinoma.

Authors:  Tatsuya Miyazaki; Takanori Inose; Naritaka Tanaka; Takehiko Yokobori; Shigemasa Suzuki; Daigo Ozawa; Makoto Sohda; Masanobu Nakajima; Minoru Fukuchi; Hiroyuki Kato; Hiroyuki Kuwano
Journal:  Surg Today       Date:  2013-01-03       Impact factor: 2.549

8.  Helicobacter pylori induces apoptosis in Barrett's-derived esophageal adenocarcinoma cells.

Authors:  Andrew D Jones; Kathy D Bacon; Blair A Jobe; Brett C Sheppard; Clifford W Deveney; Michael J Rutten
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

9.  Helicobacter pylori and gastroesophageal reflux disease: a case-control study.

Authors:  Douglas A Corley; Ai Kubo; T R Levin; Gladys Block; Laurel Habel; Gregory Rumore; Charles Quesenberry; Patricia Buffler; Julie Parsonnet
Journal:  Helicobacter       Date:  2008-10       Impact factor: 5.753

10.  CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett's esophagus in a population with high H. pylori infection rate.

Authors:  Angel Ferrández; Rafael Benito; Juan Arenas; María Asunción García-González; Federico Sopeña; Javier Alcedo; Javier Ortego; Ricardo Sainz; Angel Lanas
Journal:  BMC Gastroenterol       Date:  2006-02-16       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.